IKT.NASDAQInhibikase Therapeutics, INC

10-Q: Inhibikase Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update

Sentiment:

Quarterly Report

📋All filings for Inhibikase Therapeutics, INC
🔒Login to Follow

Inhibikase Therapeutics reports its financial results for the first quarter of 2025, highlighting progress in its PAH program and recent corporate developments.

Worse than expectedThe company's net loss increased significantly from $4.65 million in Q1 2024 to $13.68 million in Q1 2025, indicating a worsening financial performance.

Summary

  • Inhibikase Therapeutics, Inc., a clinical-stage pharmaceutical company, announced its financial results for the first quarter ended March 31, 2025.
  • The company is focused on developing therapeutics for cardiopulmonary diseases, particularly Pulmonary Arterial Hypertension (PAH), targeting aberrant signaling through Abelson Tyrosine Kinases.
  • Their lead product candidate, IKT-001, is a prodrug of imatinib mesylate for PAH, an orphan indication.
  • The company completed non-human primate safety studies and a bioequivalence clinical trial, and expects to initiate a Phase 2b study in the second half of 2025.
  • As of March 31, 2025, the company had cash, cash equivalents, and marketable securities of $93.18 million.
  • The company incurred a net loss of $13.68 million for the three months ended March 31, 2025, compared to a net loss of $4.65 million for the same period in 2024.
  • Research and development expenses increased to $10.51 million from $2.75 million in the prior year, primarily due to a one-time expense related to the acquisition of CorHepta.
  • Selling, general, and administrative expenses increased to $5.25 million from $2.03 million in the prior year, driven by increased legal, consulting, and personnel-related costs.
  • The company outlicensed risvodetinib (IkT-148009) subsequent to March 31, 2025.
  • The company believes its current cash and marketable securities are sufficient to fund operations for at least the next twelve months.

Sentiment

Score: 5

Explanation: The sentiment is neutral. While the company has a strong cash position and is advancing its PAH program, it also reported a significant increase in net loss and faces several risks related to regulatory approvals, manufacturing, and trade policies.

Positives

  • The company has a strong cash position of $93.18 million, which is expected to fund operations for at least the next twelve months.
  • The company is advancing its lead product candidate, IKT-001, for PAH, with a Phase 2b trial expected to begin in the second half of 2025.
  • The company completed a bioequivalence clinical trial, which will inform the dosing for the Phase 2b study.
  • The company has commercialization rights to IKT-001 and patent protection in the United States until 2033, with potential extensions to 2045.
  • The company successfully outlicensed risvodetinib (IkT-148009) subsequent to March 31, 2025.

Negatives

  • The company incurred a significant net loss of $13.68 million for the first quarter of 2025, a substantial increase from the $4.65 million loss in the same period of 2024.
  • Research and development expenses increased significantly, including a one-time $7.4 million write-off related to the CorHepta acquisition.
  • The company has an accumulated deficit of $108.1 million as of March 31, 2025.
  • The company has not generated any revenue from the sale of commercial products and does not expect to generate significant revenue until regulatory approval and commercialization of its product candidates.

Risks

  • The company is subject to risks associated with the successful development, regulatory approval, and market acceptance of its product candidates.
  • The company may be unable to raise additional working capital on commercially favorable terms, which could negatively impact its business.
  • The company is dependent on third-party manufacturers located in China, exposing it to political and economic risks.
  • Changes in U.S. trade policies and tariffs could negatively impact the company's ability to obtain products and raw materials.
  • The company is subject to increasing scrutiny and restrictions on personal data transfers and transactions involving foreign countries, including China.
  • The company is dependent on third-party manufacturers which are located in China, and any inability to obtain products from any such manufacturers could harm our business.

Future Outlook

The company expects to initiate a Phase 2b clinical trial for IKT-001 in PAH in the second half of 2025 and believes its current cash and marketable securities are sufficient to fund operations for at least the next twelve months.

Management Comments

  • The company intends to use the net proceeds from the October 2024 private placement to finance the initiation of a Phase 2b trial in PAH and for general corporate purposes.
  • The company plans to apply for Orphan Drug Designation (ODD) for delivery of imatinib by IKT-001 for PAH once the required pre-clinical studies are complete.

Industry Context

The company is targeting the PAH market, which was valued at $7.66 billion in 2023 and is estimated to grow at a CAGR of 5.4% between 2024 and 2030. The company is pursuing an anti-proliferative approach to PAH treatment, which has gained renewed interest following the success of sotatercept.

Comparison to Industry Standards

  • The company's approach to PAH treatment with IKT-001, a prodrug of imatinib, is based on the premise that inhibiting Abelson Tyrosine Kinase and type III receptor tyrosine kinases can modify the disease.
  • The company references the IMPRES trial, a Phase 3 trial evaluating imatinib mesylate as a treatment for PAH, which showed improvements in exercise capacity and hemodynamics but was limited by bleeding risk and high discontinuation rates.
  • The company notes a contemporary study published in the American Journal of Respiratory and Critical Care Medicine, which confirmed that imatinib 100-400mg was well tolerated in WHO Group 1 PAH population and demonstrated a treatment effect on total pulmonary resistance (TPR) that compares favorably with other novel therapies for PAH, including sotatercept and seralutinib.

Management Changes

RolePrevious PersonNew PersonEffective DateReason
Chief Executive OfficerNot explicitly mentioned, but implied to be someone elseMark IwickiNot explicitly mentionedNot explicitly mentioned

Stakeholder Impact

  • Shareholders: The company's financial performance and progress in its PAH program will impact shareholder value.
  • Employees: The company's ability to secure funding and advance its product candidates will impact job security and opportunities.
  • Patients: The company's development of IKT-001 for PAH has the potential to provide a new treatment option for patients with this rare disease.

Next Steps

  • Initiate a Phase 2b clinical trial for IKT-001 in PAH in the second half of 2025.
  • Apply for Orphan Drug Designation (ODD) for delivery of imatinib by IKT-001 for PAH.
  • Continue to develop and seek regulatory approvals for product candidates.
  • Monitor and manage risks related to third-party manufacturers and trade policies.

Key Dates

DateDescription
December 2020The Company raised approximately $14.6 million in net proceeds from public offerings of its common stock.
June 2021The Company raised approximately $41.1 million in net proceeds from public offerings of its common stock.
April 18, 2022The Company entered into an operating lease agreement for office space located in Lexington, Massachusetts.
August 8, 2022The Company commenced occupancy of the leased space in Lexington, Massachusetts.
January 2023The Company raised approximately $8.5 million in net proceeds from public offerings of its common stock.
February 1, 2024The Company entered into an ATM with H.C. Wainwright & Co., LLC, as sales agent.
February 12, 2024The FDA issued official meeting minutes summarizing the pre-NDA meeting regarding IKT-001.
January 19, 2024The company met with the FDA Hematological Malignancy Review Team in a Pre-New Drug Application (pre-NDA), meeting to discuss our bioequivalence studies of IKT-001 and its path to approval.
May 20, 2024The Company filed with the SEC a prospectus supplement to reduce the maximum aggregate gross sales price of its common stock that may be offered, issued and sold under the ATM Agreement from and after May 20, 2024 to $ 50,000.
May 20, 2024The Company entered into a securities purchase agreement with a single institutional investor in connection with a registered direct offering and concurrent private placement with the same institutional investor (collectively the 'May 2024 Offering').
May 2024The Company raised approximately $3.2 million in net proceeds from public offerings of its common stock.
June 7, 2024The stockholders of the Company approved an amendment to the 2020 Plan, pursuant to which the number of shares of Common Stock reserved and available for issuance under the 2020 Plan increased by 2,500,000 shares.
August 9, 2024The IND was filed with the FDA.
September 9, 2024The company was cleared to initiate a Phase 2b trial.
October 9, 2024The shares held in abeyance were issued to the investor.
October 21, 2024The Company announced the closing of a private placement of approximately $ 110 million.
October 2024The Company raised approximately $99.6 million in net proceeds from its October 2024 Offering.
December 2, 2024The Company provided to the Agent a notice of termination of the ATM Agreement, which such termination was effective December 11, 2024.
December 11, 2024Termination of the ATM Agreement.
January 3, 2025The stockholders of the Company approved an amendment to the 2020 Plan, pursuant to which the number of shares of Common Stock reserved and available for issuance under the 2020 Plan increased by 27,453,993 shares.
January 2025The Company issued 702,625 warrants to a non-financial investor pursuant to a pre-existing brokerage agreement.
February 21, 2025The Company entered into an Agreement and Plan of Merger and Reorganization (Merger Agreement) with Project IKT Merger Sub, Inc., a Delaware corporation and wholly-owned subsidiary of the Company (Merger Sub) and CorHepta Pharmaceuticals, Inc. a Delaware corporation (CorHepta).
March 31, 2025End of first quarter.
May 5, 2025The Company entered into a license agreement (the License Agreement) with ABLi Therapeutics, Inc. (ABLi), pursuant to which the Company granted ABLi an exclusive license to develop, manufacture and commercialize certain abelson tyrosine kinase inhibitors, including risvodetinib (IkT-148009).
Second half of 2025Expected initiation of Phase 2b clinical study for IKT-001 in PAH.

Keywords

Inhibikase Therapeutics, IKT-001, Pulmonary Arterial Hypertension, PAH, Risvodetinib, Clinical Trial, Financial Results, Research and Development, Abelson Tyrosine Kinase, CorHepta, Imatinib

Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.